Two rival cholesterol-lowering injections from Sanofi and Amgen have been recommended by Britain's healthcare cost watchdog after the manufacturers offered special discounts to the country's state-run health service. Sanofi's Praluent, which was developed with Regeneron, and Amgen's Repatha are both so-called PCSK9 medicines that work in a different way to existing cholesterol fighters such as statins. The National Institute for Health and Care Excellence (NICE) said in draft guidance on Friday that both drugs could be considered for use by people whose cholesterol is still not under control despite trying other treatments.
Originally posted here:
Sanofi, Amgen cholesterol drugs win UK backing after price cuts